3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
29
HER2-positive Breast Cancer
5
Neoplasms
3
Multiple Myeloma
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Brain Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Salivary Gland Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma
1
Interventions
Specimen Handling
5
Biopsy
5
Whole-Body Irradiation
3
Mycophenolic Acid
3
Cyclosporine
3
Cyclophosphamide
3
Azacitidine
3
venetoclax
2
ruxolitinib
2
fludarabine phosphate
2
decitabine and cedazuridine drug combination
2
Sirolimus
2
Melphalan
2
Injections
2
Granulocyte Colony-Stimulating Factor
2
Decitabine
2
Busulfan
2
veliparib
1
tocilizumab
1
tagraxofusp
1
posaconazole
1
peginterferon alfa-2b
1
iadademstat
1
gilteritinib
1
fludarabine
1
fedratinib
1
axatilimab
1
Tranexamic Acid
1
Topotecan
1
Tacrolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myelodysplastic-Myeloproliferative Diseases
×
pertuzumab
×
90 days
×
Clear all
No trials found.